Fig.1 Inhibition of Human ACE2 [Biotinylated]: SARS-CoV-2 S protein RBD Binding by SARS-CoV-2 inhibitor.

Serial dilutions of SARS-CoV-2 inhibitor (Cat. No. AC2-NA005) (1:2 serial dilutions, from 20 μg/mL to 0.039 μg/mL (180 nM to 0.35 nM)) was added into Biotinylated ACE2: SARS-CoV-2 S protein RBD binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points prior to log transformation and curve fitting.

* 该试剂盒可提供配套Buffer套装（Cat.No. EBS-001 ELISA Buffer Set-96T）

Fig.2 Detection of Monoclonal Anti-SARS-CoV-2 Antibody, Human IgG1 titer by Indirect-ELISA Assay

Immobilized SARS-CoV-2 S protein RBD at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-SARS-CoV-2 Antibody, Human IgG1 in 1:50 human serum.Detection was performed using HRP-Conjugated Anti-human IgG antibody with sensitivity of 24 ng/mL.

Fig.3 Determination of Anti-SARS-CoV-2 Neutralizing Antibody titer in different concentrations of human serum.

Neutralizing titer of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat.No.SAD-S35) measured by Anti-SARS-CoV-2 neutralizing antibody titer serologic assay kit (Cat. No. TAS-K003) in different concentrations of human serum (CV < 30%).

Fig.4 Detection SARS-CoV-2 Nucleocapsid Protein by ELISA Assay.

Immobilized Anti-SARS-CoV-2 Nucleocapsid Antibody at 4 μg/mL (100 μL/well) can bind SARS-CoV-2 Nucleocapsid Protein. And then add Biotinylated Anti-SARS-CoV-2 Nucleocapsid Antibody at 1:5000. Detection was performed using high sensitivity HRP-conjugated streptavidin with sensitivity of 12.5 pg/mL.

Fig.5 Binding with Anti-SARS-CoV-2 S1 antibody

Immobilized biotinylated SARS-CoV2 Spike protein RBD at 1 μg/mL (100 μL/well) on Streptavidin Coated Plates, Clear, 96-Well (Cat. No. SP-11), can bind anti-SARS-CoV-2 S1 antibody with a linear range of 0.1-2 ng/mL